Gilead's (NASDAQ:GILD) controversially high priced drug Sovaldi has seen a big pushback against its price point recently, but it seems as though fears of how it would perform in terms of sales were overblown. In its first 12 weeks on the market, the adoption rates already seem monstrous, with 33,672 prescriptions for the drug being filled in that time.
In this video, Motley Fool health-care analyst David Williamson discusses the sales numbers for Sovaldi and why it looks like the greatest drug launch of all time. He also addresses the fear that some have raised, that sales could peak early and then fall off hard thereafter; David tells investors why he doesn't think this is going to be a concern.
David Williamson owns shares of AbbVie. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.